| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 26 | 2017 | 239 | 5.810 |
Why?
|
| Melanoma | 74 | 2020 | 5591 | 4.170 |
Why?
|
| Skin Neoplasms | 46 | 2020 | 4888 | 2.660 |
Why?
|
| Sarcoma | 35 | 2019 | 1842 | 2.200 |
Why?
|
| Lymph Node Excision | 18 | 2016 | 2045 | 1.770 |
Why?
|
| Sentinel Lymph Node Biopsy | 18 | 2017 | 1450 | 1.690 |
Why?
|
| Colonic Neoplasms | 10 | 2018 | 1443 | 1.350 |
Why?
|
| Neoplasm Staging | 64 | 2020 | 13989 | 1.290 |
Why?
|
| Quality of Life | 16 | 2015 | 4745 | 1.290 |
Why?
|
| Retroperitoneal Neoplasms | 13 | 2019 | 299 | 1.210 |
Why?
|
| Lymphatic Metastasis | 28 | 2018 | 4967 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2020 | 10354 | 0.940 |
Why?
|
| Breast Neoplasms | 28 | 2016 | 16226 | 0.930 |
Why?
|
| Guideline Adherence | 4 | 2017 | 647 | 0.890 |
Why?
|
| Preoperative Care | 10 | 2018 | 1550 | 0.880 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2019 | 917 | 0.810 |
Why?
|
| Extremities | 7 | 2019 | 308 | 0.800 |
Why?
|
| Lymphatic Vessels | 3 | 2011 | 140 | 0.790 |
Why?
|
| Surveys and Questionnaires | 13 | 2015 | 5919 | 0.790 |
Why?
|
| Middle Aged | 121 | 2020 | 90349 | 0.780 |
Why?
|
| Humans | 209 | 2020 | 271636 | 0.740 |
Why?
|
| Aged | 115 | 2020 | 73421 | 0.740 |
Why?
|
| Lymph Nodes | 10 | 2017 | 3069 | 0.710 |
Why?
|
| Female | 150 | 2020 | 148992 | 0.710 |
Why?
|
| Survival Analysis | 25 | 2019 | 9323 | 0.700 |
Why?
|
| Prognosis | 50 | 2020 | 22525 | 0.680 |
Why?
|
| Aged, 80 and over | 69 | 2020 | 31032 | 0.680 |
Why?
|
| SEER Program | 15 | 2015 | 1046 | 0.670 |
Why?
|
| Survivors | 5 | 2015 | 1025 | 0.670 |
Why?
|
| Liposarcoma | 6 | 2019 | 247 | 0.650 |
Why?
|
| Male | 131 | 2020 | 128836 | 0.630 |
Why?
|
| Adult | 91 | 2020 | 81791 | 0.610 |
Why?
|
| Quality of Health Care | 5 | 2018 | 630 | 0.600 |
Why?
|
| Self Care | 4 | 2014 | 239 | 0.600 |
Why?
|
| Incidence | 21 | 2020 | 5856 | 0.590 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 618 | 0.590 |
Why?
|
| Neoplasms | 18 | 2017 | 15903 | 0.590 |
Why?
|
| Gastrointestinal Neoplasms | 8 | 2018 | 624 | 0.590 |
Why?
|
| Adenocarcinoma | 13 | 2018 | 7971 | 0.580 |
Why?
|
| Mastectomy | 5 | 2015 | 1548 | 0.580 |
Why?
|
| Follow-Up Studies | 40 | 2019 | 15254 | 0.580 |
Why?
|
| Inguinal Canal | 3 | 2014 | 63 | 0.580 |
Why?
|
| Survival Rate | 44 | 2018 | 12530 | 0.560 |
Why?
|
| Postoperative Complications | 9 | 2019 | 5688 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 2429 | 0.550 |
Why?
|
| Cohort Studies | 25 | 2020 | 9467 | 0.510 |
Why?
|
| Intestinal Obstruction | 3 | 2017 | 224 | 0.500 |
Why?
|
| Plant Preparations | 1 | 2014 | 31 | 0.480 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 786 | 0.480 |
Why?
|
| Odds Ratio | 11 | 2016 | 2335 | 0.470 |
Why?
|
| Phytotherapy | 1 | 2014 | 104 | 0.460 |
Why?
|
| Torso | 4 | 2019 | 72 | 0.460 |
Why?
|
| Prospective Studies | 24 | 2017 | 13385 | 0.460 |
Why?
|
| Proportional Hazards Models | 15 | 2018 | 5113 | 0.450 |
Why?
|
| Gastrointestinal Stromal Tumors | 5 | 2018 | 318 | 0.450 |
Why?
|
| Treatment Outcome | 41 | 2019 | 33846 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2012 | 1322 | 0.430 |
Why?
|
| Health Resources | 2 | 2013 | 173 | 0.410 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2012 | 43 | 0.400 |
Why?
|
| Surgical Wound Infection | 3 | 2012 | 479 | 0.400 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 559 | 0.400 |
Why?
|
| United States | 30 | 2020 | 16036 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2016 | 404 | 0.390 |
Why?
|
| Retrospective Studies | 46 | 2019 | 39731 | 0.390 |
Why?
|
| Young Adult | 31 | 2020 | 22094 | 0.390 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 293 | 0.390 |
Why?
|
| Disease-Free Survival | 22 | 2019 | 10259 | 0.380 |
Why?
|
| Population Surveillance | 3 | 2012 | 650 | 0.380 |
Why?
|
| Abdomen | 1 | 2013 | 348 | 0.380 |
Why?
|
| Rectal Neoplasms | 6 | 2018 | 1240 | 0.380 |
Why?
|
| Models, Statistical | 4 | 2016 | 1188 | 0.380 |
Why?
|
| Delivery of Health Care | 3 | 2013 | 873 | 0.370 |
Why?
|
| Antigens, Neoplasm | 10 | 1999 | 1589 | 0.370 |
Why?
|
| Medicine | 1 | 2012 | 140 | 0.360 |
Why?
|
| Healthcare Disparities | 5 | 2018 | 645 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 19 | 2018 | 3976 | 0.360 |
Why?
|
| Axilla | 6 | 2016 | 924 | 0.360 |
Why?
|
| Leiomyosarcoma | 3 | 2017 | 255 | 0.350 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 1013 | 0.340 |
Why?
|
| Appendiceal Neoplasms | 1 | 2012 | 251 | 0.340 |
Why?
|
| Anus Diseases | 1 | 2009 | 29 | 0.330 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 125 | 0.330 |
Why?
|
| Combined Modality Therapy | 20 | 2018 | 9042 | 0.330 |
Why?
|
| Rectal Diseases | 1 | 2009 | 57 | 0.330 |
Why?
|
| Neuroendocrine Tumors | 2 | 2012 | 651 | 0.330 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2009 | 43 | 0.330 |
Why?
|
| Antineoplastic Agents | 15 | 2015 | 14653 | 0.330 |
Why?
|
| Positron-Emission Tomography | 4 | 2014 | 2198 | 0.320 |
Why?
|
| Databases, Factual | 9 | 2019 | 2287 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 13 | 2018 | 5209 | 0.320 |
Why?
|
| Sickness Impact Profile | 2 | 2012 | 138 | 0.320 |
Why?
|
| Adolescent | 32 | 2020 | 32609 | 0.320 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 807 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 567 | 0.310 |
Why?
|
| Disabled Persons | 2 | 2013 | 112 | 0.310 |
Why?
|
| Seroma | 1 | 2008 | 77 | 0.310 |
Why?
|
| Neoplasm Proteins | 10 | 1999 | 3363 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 7 | 2015 | 966 | 0.300 |
Why?
|
| Health Surveys | 2 | 2016 | 402 | 0.300 |
Why?
|
| Hemangiosarcoma | 2 | 2012 | 237 | 0.300 |
Why?
|
| Self Report | 2 | 2013 | 795 | 0.300 |
Why?
|
| Lower Extremity | 6 | 2014 | 284 | 0.290 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 105 | 0.280 |
Why?
|
| Piperazines | 5 | 2011 | 2151 | 0.270 |
Why?
|
| Histiocytoma, Malignant Fibrous | 3 | 2016 | 49 | 0.270 |
Why?
|
| Intraoperative Period | 1 | 2006 | 259 | 0.270 |
Why?
|
| Risk Assessment | 10 | 2020 | 6876 | 0.270 |
Why?
|
| Neoplasm Metastasis | 10 | 2018 | 5328 | 0.270 |
Why?
|
| Multivariate Analysis | 12 | 2020 | 4352 | 0.270 |
Why?
|
| Quality Control | 3 | 2012 | 467 | 0.270 |
Why?
|
| Reproducibility of Results | 9 | 2015 | 6208 | 0.260 |
Why?
|
| Health Status Disparities | 4 | 2016 | 309 | 0.260 |
Why?
|
| Interferons | 1 | 2007 | 300 | 0.260 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 228 | 0.260 |
Why?
|
| Bacterial Infections | 1 | 2009 | 507 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2012 | 1020 | 0.250 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 5195 | 0.250 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 30 | 0.250 |
Why?
|
| Risk Factors | 18 | 2020 | 18016 | 0.250 |
Why?
|
| Colectomy | 2 | 2018 | 290 | 0.240 |
Why?
|
| Logistic Models | 10 | 2018 | 3460 | 0.240 |
Why?
|
| Confidence Intervals | 7 | 2018 | 758 | 0.240 |
Why?
|
| Interleukin-2 | 4 | 2012 | 890 | 0.240 |
Why?
|
| Psychometrics | 5 | 2013 | 964 | 0.230 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2006 | 199 | 0.230 |
Why?
|
| Palliative Care | 3 | 2012 | 2156 | 0.230 |
Why?
|
| Bayes Theorem | 4 | 2016 | 1051 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2008 | 668 | 0.230 |
Why?
|
| Membrane Glycoproteins | 5 | 2006 | 1103 | 0.230 |
Why?
|
| Stomach Neoplasms | 6 | 2018 | 2317 | 0.230 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1177 | 0.230 |
Why?
|
| Tumor Burden | 5 | 2019 | 2035 | 0.220 |
Why?
|
| Interferon-alpha | 1 | 2008 | 961 | 0.220 |
Why?
|
| Salvage Therapy | 5 | 2018 | 2118 | 0.220 |
Why?
|
| Body Mass Index | 3 | 2017 | 2254 | 0.220 |
Why?
|
| Age Factors | 9 | 2016 | 5509 | 0.220 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1059 | 0.210 |
Why?
|
| Retroperitoneal Space | 2 | 2017 | 156 | 0.210 |
Why?
|
| Models, Theoretical | 1 | 2007 | 809 | 0.210 |
Why?
|
| Pyrimidines | 5 | 2011 | 3663 | 0.210 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 3697 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 16606 | 0.210 |
Why?
|
| Intermittent Pneumatic Compression Devices | 2 | 2012 | 7 | 0.210 |
Why?
|
| Physical Therapy Modalities | 2 | 2013 | 92 | 0.210 |
Why?
|
| Educational Status | 3 | 2014 | 393 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2014 | 2270 | 0.200 |
Why?
|
| Societies, Medical | 1 | 2008 | 1349 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 7788 | 0.190 |
Why?
|
| Registries | 5 | 2018 | 2246 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 364 | 0.190 |
Why?
|
| Models, Nursing | 1 | 2001 | 10 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 7929 | 0.190 |
Why?
|
| Total Quality Management | 1 | 2001 | 39 | 0.190 |
Why?
|
| Anthracyclines | 2 | 2015 | 339 | 0.190 |
Why?
|
| Ifosfamide | 1 | 2001 | 357 | 0.180 |
Why?
|
| Length of Stay | 5 | 2018 | 2010 | 0.180 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 1255 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 4495 | 0.180 |
Why?
|
| Age of Onset | 2 | 2013 | 852 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 4070 | 0.180 |
Why?
|
| Genetic Variation | 4 | 2006 | 2155 | 0.180 |
Why?
|
| Clinical Protocols | 3 | 2018 | 485 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 5744 | 0.170 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 2051 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 234 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2014 | 1842 | 0.170 |
Why?
|
| Risk | 5 | 2016 | 1950 | 0.170 |
Why?
|
| Social Class | 3 | 2016 | 322 | 0.170 |
Why?
|
| Wound Healing | 3 | 2017 | 758 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2001 | 144 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2008 | 1462 | 0.170 |
Why?
|
| Hospice Care | 2 | 2011 | 160 | 0.160 |
Why?
|
| Nomograms | 2 | 2013 | 313 | 0.160 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 10743 | 0.160 |
Why?
|
| Time Factors | 13 | 2015 | 13116 | 0.160 |
Why?
|
| Pancreatic Fistula | 1 | 2019 | 102 | 0.160 |
Why?
|
| Pancreatectomy | 2 | 2019 | 696 | 0.160 |
Why?
|
| Health Status Indicators | 2 | 2011 | 235 | 0.160 |
Why?
|
| MART-1 Antigen | 8 | 1999 | 113 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1999 | 247 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 442 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 380 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Upper Extremity | 4 | 2014 | 83 | 0.150 |
Why?
|
| HLA-A2 Antigen | 2 | 1999 | 171 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2011 | 5566 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 294 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 609 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 77 | 0.150 |
Why?
|
| Monophenol Monooxygenase | 1 | 1998 | 60 | 0.150 |
Why?
|
| Exercise Therapy | 2 | 2011 | 292 | 0.150 |
Why?
|
| Health Care Costs | 3 | 2014 | 698 | 0.150 |
Why?
|
| Skin Care | 2 | 2017 | 14 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2001 | 447 | 0.140 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 908 | 0.140 |
Why?
|
| Occupational Injuries | 1 | 2016 | 16 | 0.140 |
Why?
|
| Ergonomics | 1 | 2016 | 27 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 192 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2015 | 1571 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 916 | 0.130 |
Why?
|
| Neurofibrosarcoma | 1 | 2016 | 33 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 4636 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 317 | 0.130 |
Why?
|
| Neoplasm Grading | 6 | 2018 | 1827 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 479 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2016 | 133 | 0.130 |
Why?
|
| Dopamine | 1 | 1997 | 341 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 271 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 361 | 0.130 |
Why?
|
| Vascular Neoplasms | 1 | 2016 | 113 | 0.120 |
Why?
|
| Brachytherapy | 3 | 2012 | 1005 | 0.120 |
Why?
|
| Arm | 1 | 2015 | 138 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 6266 | 0.120 |
Why?
|
| Child | 14 | 2016 | 30401 | 0.120 |
Why?
|
| Health Status | 2 | 2011 | 633 | 0.120 |
Why?
|
| Rehabilitation Nursing | 1 | 2014 | 11 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 550 | 0.120 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 152 | 0.120 |
Why?
|
| Texas | 5 | 2018 | 6434 | 0.120 |
Why?
|
| Sex Factors | 4 | 2015 | 2202 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1657 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2014 | 180 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4805 | 0.120 |
Why?
|
| Medicare | 3 | 2015 | 932 | 0.120 |
Why?
|
| Case-Control Studies | 9 | 2020 | 6230 | 0.120 |
Why?
|
| Imatinib Mesylate | 6 | 2015 | 1690 | 0.120 |
Why?
|
| Lung Neoplasms | 7 | 2013 | 12008 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2010 | 5601 | 0.120 |
Why?
|
| Surgical Oncology | 1 | 2016 | 208 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 681 | 0.110 |
Why?
|
| Frailty | 1 | 2016 | 131 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 263 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 115 | 0.110 |
Why?
|
| Platinum Compounds | 1 | 2014 | 129 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2013 | 14 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 759 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2010 | 739 | 0.110 |
Why?
|
| Neck Dissection | 1 | 2014 | 294 | 0.110 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 106 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 440 | 0.110 |
Why?
|
| Reoperation | 1 | 2018 | 1389 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 2174 | 0.110 |
Why?
|
| Imagination | 1 | 2013 | 23 | 0.110 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 29 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2016 | 2853 | 0.110 |
Why?
|
| Organ Sparing Treatments | 2 | 2014 | 280 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 366 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 486 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2015 | 299 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 249 | 0.110 |
Why?
|
| Income | 1 | 2014 | 230 | 0.110 |
Why?
|
| Pain | 2 | 2012 | 1696 | 0.110 |
Why?
|
| Sexuality | 1 | 2012 | 38 | 0.110 |
Why?
|
| Medical Errors | 1 | 2015 | 227 | 0.110 |
Why?
|
| Cost of Illness | 2 | 2013 | 505 | 0.100 |
Why?
|
| Compression Bandages | 1 | 2012 | 9 | 0.100 |
Why?
|
| Ultrasonography, Mammary | 1 | 2015 | 386 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 3 | 2014 | 4136 | 0.100 |
Why?
|
| Disease Progression | 6 | 2018 | 6905 | 0.100 |
Why?
|
| Travel | 1 | 2014 | 200 | 0.100 |
Why?
|
| Polymorphism, Genetic | 3 | 2006 | 1559 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 138 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2011 | 181 | 0.100 |
Why?
|
| Morbidity | 1 | 2013 | 404 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2014 | 443 | 0.100 |
Why?
|
| Penis | 1 | 2013 | 142 | 0.100 |
Why?
|
| Lymphatic System | 1 | 2012 | 56 | 0.100 |
Why?
|
| Decision Support Techniques | 2 | 2007 | 604 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2015 | 1378 | 0.100 |
Why?
|
| Diet, Reducing | 1 | 2012 | 85 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2014 | 262 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1055 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 2331 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2015 | 1587 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2013 | 1292 | 0.100 |
Why?
|
| Patient Care | 1 | 2012 | 151 | 0.100 |
Why?
|
| Fluorescence | 1 | 2011 | 199 | 0.100 |
Why?
|
| Radiography | 3 | 2011 | 1991 | 0.090 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 14 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2003 | 490 | 0.090 |
Why?
|
| Dermatology | 1 | 2011 | 72 | 0.090 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 182 | 0.090 |
Why?
|
| gp100 Melanoma Antigen | 4 | 1998 | 94 | 0.090 |
Why?
|
| Amifostine | 1 | 2011 | 99 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 2 | 2008 | 852 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 129 | 0.090 |
Why?
|
| Child, Preschool | 7 | 2016 | 16943 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 197 | 0.090 |
Why?
|
| Disease Management | 2 | 2013 | 1111 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4963 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2009 | 458 | 0.090 |
Why?
|
| California | 1 | 2010 | 211 | 0.090 |
Why?
|
| Health Policy | 1 | 2013 | 280 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1838 | 0.090 |
Why?
|
| Marital Status | 1 | 2010 | 93 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2837 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 282 | 0.090 |
Why?
|
| Anal Canal | 1 | 2011 | 238 | 0.090 |
Why?
|
| Surgeons | 1 | 2016 | 487 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 729 | 0.090 |
Why?
|
| Taxoids | 1 | 2014 | 1010 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2012 | 1017 | 0.090 |
Why?
|
| Benzamides | 5 | 2011 | 1882 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2010 | 98 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 612 | 0.080 |
Why?
|
| Xerostomia | 1 | 2011 | 205 | 0.080 |
Why?
|
| Analysis of Variance | 5 | 2008 | 2334 | 0.080 |
Why?
|
| Movement | 1 | 2013 | 563 | 0.080 |
Why?
|
| Demography | 1 | 2010 | 435 | 0.080 |
Why?
|
| Social Support | 2 | 2012 | 590 | 0.080 |
Why?
|
| Inflammation | 1 | 2019 | 2532 | 0.080 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 174 | 0.080 |
Why?
|
| Mammography | 1 | 2015 | 1045 | 0.080 |
Why?
|
| Robotics | 1 | 2013 | 365 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Infant | 5 | 2016 | 13887 | 0.080 |
Why?
|
| Weight Loss | 1 | 2013 | 638 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1387 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 2668 | 0.080 |
Why?
|
| Consensus | 1 | 2013 | 1115 | 0.080 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2008 | 19 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 24 | 0.080 |
Why?
|
| Electric Impedance | 1 | 2009 | 101 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2008 | 139 | 0.080 |
Why?
|
| Groin | 1 | 2008 | 78 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 48 | 0.080 |
Why?
|
| Kidney | 1 | 1997 | 2265 | 0.080 |
Why?
|
| Suction | 1 | 2008 | 111 | 0.080 |
Why?
|
| Poxviridae | 2 | 1998 | 9 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2398 | 0.080 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 553 | 0.080 |
Why?
|
| Patient Participation | 1 | 2012 | 449 | 0.080 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2008 | 28 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 604 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 658 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 3423 | 0.070 |
Why?
|
| Cells, Cultured | 6 | 2012 | 5779 | 0.070 |
Why?
|
| Benchmarking | 1 | 2009 | 284 | 0.070 |
Why?
|
| Cross Infection | 1 | 2012 | 548 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2003 | 2417 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2007 | 227 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2015 | 1858 | 0.070 |
Why?
|
| Anus Neoplasms | 1 | 2011 | 417 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 7817 | 0.070 |
Why?
|
| Markov Chains | 1 | 2007 | 183 | 0.070 |
Why?
|
| Hyperthermia, Induced | 2 | 2011 | 510 | 0.070 |
Why?
|
| Health Services Research | 1 | 2008 | 243 | 0.070 |
Why?
|
| Physical Examination | 1 | 2008 | 303 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1340 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 65 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2006 | 152 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1999 | 683 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1232 | 0.060 |
Why?
|
| Chromatids | 1 | 2005 | 84 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 790 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2008 | 379 | 0.060 |
Why?
|
| Epitopes | 2 | 1999 | 708 | 0.060 |
Why?
|
| Pelvis | 1 | 2007 | 384 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 465 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 67 | 0.060 |
Why?
|
| Genotype | 4 | 2020 | 4263 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4998 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2004 | 3852 | 0.060 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2006 | 192 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2002 | 3150 | 0.060 |
Why?
|
| Biometry | 1 | 2006 | 247 | 0.060 |
Why?
|
| Health Personnel | 1 | 2010 | 648 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 320 | 0.060 |
Why?
|
| Exercise | 1 | 2012 | 1214 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 565 | 0.060 |
Why?
|
| Thoracic Neoplasms | 1 | 2007 | 347 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 556 | 0.060 |
Why?
|
| Interferon-gamma | 3 | 1998 | 1180 | 0.060 |
Why?
|
| Immunotherapy | 1 | 1998 | 3539 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 887 | 0.060 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 562 | 0.060 |
Why?
|
| Neutropenia | 1 | 2008 | 1001 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 1999 | 5804 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2010 | 1935 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2007 | 957 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 1401 | 0.060 |
Why?
|
| Cisplatin | 2 | 2010 | 2497 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 1214 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4191 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 591 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2008 | 1006 | 0.050 |
Why?
|
| Minority Groups | 1 | 2005 | 321 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 532 | 0.050 |
Why?
|
| Leg | 1 | 2004 | 216 | 0.050 |
Why?
|
| Obesity | 2 | 2017 | 2952 | 0.050 |
Why?
|
| Propensity Score | 2 | 2018 | 775 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2016 | 2348 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 5996 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2004 | 179 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 2 | 1999 | 85 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1472 | 0.050 |
Why?
|
| Pancreatic Ducts | 1 | 2003 | 128 | 0.050 |
Why?
|
| Medical Records | 3 | 2008 | 447 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2009 | 1038 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2018 | 592 | 0.050 |
Why?
|
| Magnesium | 1 | 2002 | 172 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2001 | 74 | 0.050 |
Why?
|
| Orthopedic Nursing | 1 | 2001 | 1 | 0.050 |
Why?
|
| Nursing, Supervisory | 1 | 2001 | 2 | 0.050 |
Why?
|
| Operating Room Nursing | 1 | 2001 | 2 | 0.050 |
Why?
|
| Nurse Administrators | 1 | 2001 | 5 | 0.050 |
Why?
|
| Planning Techniques | 1 | 2001 | 13 | 0.050 |
Why?
|
| Nursing Evaluation Research | 1 | 2001 | 11 | 0.050 |
Why?
|
| Hospitals, Religious | 1 | 2001 | 8 | 0.050 |
Why?
|
| Immunodominant Epitopes | 2 | 1998 | 64 | 0.050 |
Why?
|
| Time Management | 1 | 2001 | 15 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 1998 | 1110 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 31 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2006 | 575 | 0.050 |
Why?
|
| Case Management | 1 | 2001 | 37 | 0.050 |
Why?
|
| Alleles | 3 | 2006 | 2598 | 0.050 |
Why?
|
| Informed Consent | 1 | 2004 | 413 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4391 | 0.050 |
Why?
|
| Problem Solving | 1 | 2001 | 89 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 1580 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2001 | 94 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3391 | 0.040 |
Why?
|
| Skin | 1 | 2005 | 1284 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 629 | 0.040 |
Why?
|
| Histocompatibility Testing | 2 | 1999 | 484 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 4502 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 261 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3538 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2010 | 2168 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 2043 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 98 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2001 | 210 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 308 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2002 | 835 | 0.040 |
Why?
|
| Algorithms | 2 | 2008 | 3922 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 1999 | 105 | 0.040 |
Why?
|
| DNA Repair | 1 | 2006 | 1912 | 0.040 |
Why?
|
| Second-Look Surgery | 1 | 2018 | 15 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 342 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2015 | 4003 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1740 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 2672 | 0.040 |
Why?
|
| Oliguria | 1 | 1997 | 20 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4795 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2001 | 426 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 228 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2006 | 1184 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 1996 | 49 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 349 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2002 | 1280 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 314 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 63 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 5067 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 275 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 3544 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 292 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 96 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2001 | 829 | 0.030 |
Why?
|
| Comorbidity | 2 | 2014 | 2435 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1965 | 0.030 |
Why?
|
| Economics, Pharmaceutical | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 453 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 372 | 0.030 |
Why?
|
| Communication | 1 | 2001 | 854 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 1998 | 1327 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 690 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 759 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 718 | 0.030 |
Why?
|
| Animals | 4 | 2011 | 62757 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1209 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 102 | 0.030 |
Why?
|
| Kinesthesis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Death Certificates | 1 | 2013 | 17 | 0.030 |
Why?
|
| Translations | 1 | 2013 | 43 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2015 | 209 | 0.030 |
Why?
|
| France | 1 | 2013 | 121 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2012 | 17 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1998 | 1053 | 0.030 |
Why?
|
| Monocytes | 1 | 1996 | 788 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1995 | 588 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1315 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1849 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 704 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 188 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 176 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 7834 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1089 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2013 | 265 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Aziridines | 1 | 1990 | 20 | 0.020 |
Why?
|
| Fatty Acids, Essential | 1 | 1990 | 5 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1990 | 37 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1988 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2011 | 162 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 786 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2012 | 505 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 1613 | 0.020 |
Why?
|
| Proteins | 1 | 1998 | 2057 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 545 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 462 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 74 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 296 | 0.020 |
Why?
|
| Rural Population | 1 | 2010 | 292 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2008 | 170 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5180 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1990 | 238 | 0.020 |
Why?
|
| Melphalan | 1 | 2011 | 875 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 228 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 2049 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 671 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 916 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 1047 | 0.020 |
Why?
|
| Antigen Presentation | 2 | 1998 | 289 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 197 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2006 | 74 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 64 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 879 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 433 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3645 | 0.020 |
Why?
|
| Sunlight | 1 | 2006 | 80 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 35 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1513 | 0.020 |
Why?
|
| Endonucleases | 1 | 2006 | 184 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2006 | 72 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 447 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 154 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 15913 | 0.020 |
Why?
|
| Microsurgery | 1 | 2007 | 234 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 163 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 247 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1510 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2008 | 476 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 495 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1327 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 556 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 621 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 751 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2006 | 306 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 2202 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2011 | 3131 | 0.010 |
Why?
|
| Lymph | 1 | 2003 | 70 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2267 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 544 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1742 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8587 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 207 | 0.010 |
Why?
|
| Sepsis | 1 | 2008 | 688 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2016 | 2912 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 2099 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1990 | 846 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 5499 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 2365 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 5246 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 731 | 0.010 |
Why?
|
| Rats, Inbred BB | 2 | 1990 | 9 | 0.010 |
Why?
|
| Fowlpox virus | 1 | 1998 | 6 | 0.010 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 1998 | 23 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 85 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1998 | 56 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1998 | 85 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 275 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 291 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1996 | 65 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 229 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 426 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 668 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 184 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3472 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1997 | 314 | 0.010 |
Why?
|
| Immunization | 1 | 1996 | 402 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 1996 | 435 | 0.010 |
Why?
|
| Vaccination | 1 | 1999 | 1154 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1995 | 1241 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 5504 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 1883 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 4635 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1729 | 0.010 |
Why?
|
| Rats | 2 | 1990 | 6633 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 6781 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 1996 | 751 | 0.010 |
Why?
|
| Peptides | 1 | 1996 | 1528 | 0.010 |
Why?
|
| Linoleic Acids | 1 | 1990 | 32 | 0.010 |
Why?
|
| Linoleic Acid | 1 | 1990 | 29 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1990 | 125 | 0.010 |
Why?
|
| Thyroxine | 1 | 1990 | 117 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 503 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1990 | 448 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1990 | 692 | 0.000 |
Why?
|
| Body Weight | 1 | 1990 | 1334 | 0.000 |
Why?
|
| Macrophages | 1 | 1990 | 1376 | 0.000 |
Why?
|